Anti-Human IL-6R (Sarilumab) – Fc Muted™ HRP
Anti-Human IL-6R (Sarilumab) – Fc Muted™ HRP
Product No.: LT1707
Product No.LT1707 Clone Hu137 Target IL-6 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2 Isotype Human IgG1κ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Muted Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2892934 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B N IHC (Paraffin) IHC (Frozen) WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only. Background IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner.1 Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19.3 Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects. Antigen Distribution IL-6R is ubiquitously expressed. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cell Biology . Immunology . Innate Immunity . Neuroscience . Other Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Sarilumab biosimilars are commonly used as calibration standards (analytical standards) or reference controls in PK bridging ELISA assays by preparing a dilution series with known concentrations to generate a standard curve for quantifying Sarilumab levels in serum samples. In practice:
Key points for PK bridging ELISA with Sarilumab biosimilars:
ELISA Procedure Summary (typical for Sarilumab):
This approach—using research-grade Sarilumab biosimilars for analytical standards and controls—assures robust, comparative, and regulatory-compliant measurement of drug concentrations in human serum samples in PK bridging ELISA studies. Biopharma companies perform a comprehensive array of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator (reference) biologic drug. These assays rigorously characterize both the molecular features and biological activity to ensure safety, efficacy, and regulatory compliance. Typical analytical assays include:
The use of multiple, orthogonal assays—where different types of tests are used to confirm the same attribute—ensures robust and reliable evidence of similarity. Leinco biosimilar reagents in analytical studies: Leinco may refer to commercially available biosimilar reference standards or analytical controls, such as characterized monoclonal antibodies or proteins, that serve key roles in biosimilar analytical studies. Leinco biosimilars are used as high-quality reference materials to:
By providing characterized biosimilar-like molecules, Leinco biosimilars help ensure the quality, reliability, and regulatory acceptability of similarity assessments. In summary: Analytical similarity assessment involves extensive physicochemical and functional testing—including structure, purity, modification profile, and potency—using cutting-edge, validated assays. Leinco biosimilars are often used as reference standards, assay controls, or comparators throughout this process to ensure robust, transparent, and reproducible similarity data. References & Citations1. Kevzara (sarilumab) injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; Bridgewater, NJ: sanofi-aventis U.S.; May 2017. 2. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313. 3. "Northwell Health Initiates Clinical Trials of 2 COVID-19 Drugs". 21 March 2020. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1700 | |
LT1703 | |
LT1704 | |
LT1702 | |
LT1701 | |
LT1711 | |
LT1706 | |
LT1705 | |
LT1707 |
